BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37145301)

  • 1. SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer.
    Zheng Z; Li X; Yang B; Xu Q; Zhu X; Hu L; Teng Y
    Funct Integr Genomics; 2023 May; 23(2):147. PubMed ID: 37145301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
    Wang J; Liu L
    J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
    Li W; Huang L; Qi N; Zhang Q; Qin Z
    BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin.
    Kobayashi Y; Seino K; Hosonuma S; Ohara T; Itamochi H; Isonishi S; Kita T; Wada H; Kojo S; Kiguchi K
    Gynecol Oncol; 2011 May; 121(2):390-4. PubMed ID: 21272926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation.
    Li H; Lin R; Zhang Y; Zhu Y; Huang S; Lan J; Lu N; Xie C; He S; Zhang W
    Mol Cancer; 2024 Jan; 23(1):5. PubMed ID: 38184597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
    Chen Y; Bieber MM; Teng NN
    Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
    Guo J; Pan H
    Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
    Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
    Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of EMP1 as a critical gene for cisplatin resistance in ovarian cancer by using integrated bioinformatics analysis.
    Zeng Q; Yi C; Lu J; Wang X; Chen K; Hong L
    Cancer Med; 2023 Apr; 12(7):9024-9040. PubMed ID: 36708070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
    Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.
    Kim JY; Bahar E; Lee JY; Chang S; Kim SH; Park EY; Do SI; Yoon H; Kim HS
    Cell Death Dis; 2022 Mar; 13(3):239. PubMed ID: 35293383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
    Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
    Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
    Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.
    Xiao S; Zhang M; Liu C; Wang D
    Mol Genet Genomics; 2018 Oct; 293(5):1159-1167. PubMed ID: 29752546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
    Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
    EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
    Bai L; Wang A; Zhang Y; Xu X; Zhang X
    Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
    Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
    Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells.
    Tanaka M; Kataoka H; Yano S; Ohi H; Kawamoto K; Shibahara T; Mizoshita T; Mori Y; Tanida S; Kamiya T; Joh T
    BMC Cancer; 2013 May; 13():237. PubMed ID: 23672493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.